Frontline Treatment with Brentuximab Vedotin Plus CHP Provides Clinically Meaningful Improvement in Survival Compared to CHOP in Patients with PTCL
5-year update from the ECHELON-2 study in patients with peripheral T-cell lymphoma
Oncology News
ESMO oncology news aims to keep you up to date with the developments that affect you and your daily practice.
Make sure you check these pages frequently, or sign up to our newsletter! To sign up for ESMO newsletters, create a myESMO account here and select the newsletters you’d like to receive.
1548 results
EMA Recommends Extension of Therapeutic Indications for Avapritinib
It adopted two new strengths and a new indication for the treatment of advanced systemic mastocytosis
Cemiplimab Prolongs Overall Survival Among Patients with Recurrent Cervical Cancer After First-Line Platinum-Containing Chemotherapy
Findings from the EMPOWER-Cervical 1/GOG-3016/ENGOT-cx9 study
Neoadjuvant Pembrolizumab Combined with Chemotherapy Followed by Adjuvant Pembrolizumab Significantly Improves Event-Free Survival in High-Risk, Early TNBC
Findings from the KEYNOTE-522 study among patients with stage II and III triple-negative breast cancer
Copanlisib Shows Promising Clinical Activity in Select Tumours with PIK3CA Mutation in Refractory Setting
Results from the NCI-MATCH ECOG-ACRIN study (EAY131) subprotocol Z1F
Greater Severity of Adverse Events in Women Across Multiple Anticancer Treatment Modalities
Large sex differences were observed among patients who received particularly immunotherapy
EMA Recommends Granting a Marketing Authorisation for Generic Dasatinib
Dasatinib Accord and Dasatinib Accordpharma are generic of Sprycel, which has been authorised in the EU since 2006
With 3 Years Minimum Follow-Up, Nivolumab Plus Ipilimumab Continues to Provide Long-Term Survival Benefit Over Chemotherapy in Unresectable Malignant Pleural Mesothelioma
Updated efficacy and safety data from the CheckMate 743 study
Robust and Sustained Survival Benefit with Consolidation Durvalumab After Concurrent Chemoradiotherapy for Unresectable, Stage III NSCLC
Five-year survival data from the PACIFIC study
FDA Approves Tebentafusp-tebn for Unresectable or Metastatic Uveal Melanoma
Evidence for efficacy is based on the results from the IMCgp100-202 study
EMA Recommends Granting a Marketing Authorisation for Lisocabtagene Maraleucel
It is indicated for the treatment of adult patients with relapsed or refractory diffuse large B cell lymphoma, primary mediastinal large B cell lymphoma and follicular lymphoma grade 3B, after two or more lines of systemic therapy
Triple Therapy with Pertuzumab, Trastuzumab and Docetaxel is Feasible and Tolerable for HER2-Mutated, Pretreated Advanced NSCLC
Findings from the IFCT-1703 R2D2 study